



TARGET MARKETS

- Prevention of GvHD post bone marrow transplantation – \$1 billion
- Severe Sepsis – \$12 billion
- CAR-T – \$4 billion

CLINICAL PROGRAMS

- Prevention of GvHD post bone marrow transplantation – Preparing for initiation of **Phase III** in the U.S.
- Sepsis – Preparing for the initiation of Phase II in Israel
- CAR-T – Seeking partner for **Phase II**

LEAD SHAREHOLDERS

- KIP Global Pharma-Ecosystem Private Equity Fund
- HBL-Hadasit Bio-Holdings Ltd.
- Shai Novik

FUNDING TO DATE

- \$25 million

TRANSACTION

- Pre-IPO/RTO (Nasdaq/NYSE) 1st quarter 2018
- IPO/RTO timeline – 2nd-3rd quarter 2018
- IPO/RTO led by Enlivex insiders

ABSTRACT

Enlivex Pharmaceuticals Ltd is a clinical-stage immunotherapy company, developing a drug pipeline for the treatment of immune and inflammatory conditions which involve over-expression or hyper-expression of cytokines (Cytokine Release Syndrome) such as CAR-T cancer treatment procedures, Graft-versus-Host disease (GvHD) resulting from bone-marrow transplantations, Sepsis, and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis, and other disorders.

Indication	Market Size	Preclin.	Ph I	Ph II	Ph III
ALLOCETRA™ for Prevention of GvHD + Lower Mortality post HSCT	\$1B	→	→	→	→
ALLOCETRA™ for Sepsis (Endpoint: Safety at 28 days)	\$12B	→	→	→	Direct path into Phase II Due To Excellent Safety Profile of ALLOCETRA™
ALL, CLL Last Line CD19 CAR-T + ALLOCETRA™ (Endpoint: % Complete Remission, % with Cytokine Storm/Neurotox)	\$4B	→ Seeking partner			

COMPETITIVE ADVANTAGES

- Acute GvHD and Sepsis are clinical conditions with unmet clinical need and no FDA-approved therapies.
- These are multi-factorial complications of the immune system, unresolved by traditional small molecule or antibody therapies
- The unique approach of Enlivex enhances the ability of the immune system to rebalance itself through its core rebalancing mechanism of action

MANAGEMENT TRACK-RECORD

- Shai Novik, Executive Chairman: Previously founded PROLOR Biotech in 2005, and has served as its President through its acquisition. Listed PROLOR Biotech on NYSE in 2010, and sold it to U.S. specialty pharma OPKO Health in 2013 for \$560 million. Signed a partnership with Pfizer for the lead compound, \$295 million down payment – the highest-ever paid for a Phase III endocrinology partnering deal in the U.S.
- Eyal Fima, CEO, Ph.D.: Previously served as COO and CEO of PROLOR Biotech
- Prof. Dror Mevorach, M.D.: Chairman of Medicine at the Hadassah – Hebrew University Medical Center in Jerusalem. Dr. Mevorach has been investigating the role of apoptosis and cytokines for the past 18 years, and is a world leader in apoptosis research.

